冠狀動脈疾病治療市場：依藥物類型、通路和地區分類

冠狀動脈疾病治療市場預計到 2026 年將達到 151 億美元，預計到 2033 年將達到 223 億美元。預計從 2026 年到 2033 年，該市場將以 5.7% 的複合年成長率成長。

由於冠狀動脈疾病（CAD）盛行率上升、心血管疾病發生率增加、人口老化以及降脂療法和心血管預防治療的不斷進步，預計市場將穩步成長。肥胖、糖尿病、高血壓、血脂異常症和久坐不動的生活方式等問題日益嚴重，進一步擴大了需要長期心血管照護的患者族群。

冠狀動脈疾病的治療涵蓋多種藥物療法，旨在預防、控制和減輕與冠狀動脈狹窄和斑塊形成相關的各種心血管併發症。這些療法包括他汀類藥物、 BETA阻斷劑、血管緊張素轉換酶抑制劑、硝酸酯類藥物、鈣離子通道阻斷劑以及其他心血管藥物，這些藥物有助於控制膽固醇水平、調節血壓、改善血流，並降低心肌梗塞和其他心血管事件的風險。隨著人們對預防心臟病學和早期療育的日益重視，全球對有效冠狀動脈疾病治療的需求持續成長。

心血管研究投入的增加、有利的保險報銷政策、人們對心臟健康的日益重視，以及PCSK9抑制劑、基於RNA的降膽固醇藥物和基因編輯等創新療法的引入，進一步推動了市場的擴張。此外，數位醫療技術、遠端患者監護解決方案以及人工智慧驅動的心血管護理的整合，也為市場成長創造了有利環境。

市場動態

冠狀動脈疾病治療市場受到流行病學、技術、監管和醫療保健可近性等多種因素的影響。

冠狀動脈疾病及其相關心血管危險因子在全球範圍內的日益普及是推動成長的主要成長要素之一。肥胖、糖尿病、高血壓、吸菸和久坐不動的生活方式等因素持續增加，顯著推高了冠狀動脈疾病（CAD）的發生率。由於心血管疾病仍然是全球主要的死亡原因之一，預防和長期心血管護理在醫療保健系統中日益受到重視，從而導致對治療性介入的持續需求。

另一個重要的成長要素是先進的降脂和心臟保護療法的廣泛應用。 PCSK9抑制劑、基於siRNA的療法（例如inclisiran）以及靶向膽固醇代謝路徑的新型基因編輯技術的引入，正在改善高風險患者的治療效果。越來越多的臨床證據支持強化膽固醇管理和降低心血管風險，這進一步促使醫師採用創新療法。

技術進步也顯著推動了市場成長。人工智慧、遠端心臟診斷平台、穿戴式心電圖監測設備和數位化患者支援計畫的整合，正在提升疾病管理水平，改善患者用藥依從性，並促進早期療育。這些創新使醫療服務提供者能夠提供更個人化和高效的心血管護理。

然而，心血管市場也面臨許多挑戰，例如先進心血管治療高成本、中低收入國家醫療服務取得受限、法規核准流程漫長以及醫療保險公司的價格壓力。儘管存在這些挑戰，但心血管醫學領域的持續創新、醫療基礎設施的不斷完善以及預防醫學意識的日益增強，預計將支撐市場的長期成長。

本次調查的主要特點

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數分析了冠狀動脈疾病治療市場主要公司的概況：公司概況、服務組合、主要發展、財務表現和策略。
• 透過利用本報告中的見解，行銷負責人和經營團隊將能夠就未來的服務創新、市場擴張和策略合作夥伴關係做出明智的決策。
• 《冠狀動脈疾病治療市場》報告的目標對象包括投資者、服務供應商、製藥公司、監管機構和金融分析師等各類相關人員。
• 相關人員可以利用系統分析框架和策略矩陣來評估冠狀動脈疾病治療市場，從而獲得巨大利益。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場概覽

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 市場機遇
• 影響分析
• 市場趨勢
• 主要進展
• 疾病特定批准
• 合作關係、併購
• 監理情勢
• PEST分析
• 波特五力分析
• 流行病學
• 穩健的管道分析

第4章 全球冠狀動脈疾病治療市場：依藥物類型分類，2021-2033年

• BETA阻斷劑
• 他汀類藥物
• ACE抑制劑
• 硝酸酯類藥物
• 鈣離子通道阻斷劑
• 其他

第5章 全球冠狀動脈疾病治療市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第6章 全球冠狀動脈疾病治療市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第7章 競爭情勢

• 熱圖分析
• 市佔率分析
• 公司簡介
  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer
  • Bayer
  • Merck & Co.
  • GlaxoSmithKline plc
  • Mylan NV
• 分析師意見

第8章

• 參考
• 調查方法
• 關於本公司

Coronary Artery Disease Therapeutics Market is estimated to be valued at USD 15.1 Bn in 2026 and is expected to reach USD 22.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.

The market is expected to witness steady growth due to the rising prevalence of coronary artery disease (CAD), increasing incidence of cardiovascular disorders, growing aging population, and continuous advancements in lipid-lowering and preventive cardiovascular therapies. The increasing burden of obesity, diabetes, hypertension, dyslipidemia, and sedentary lifestyles is further expanding the patient pool requiring long-term cardiovascular treatment.

Coronary artery disease therapeutics comprise a broad range of pharmaceutical treatments designed to prevent, manage, and reduce cardiovascular complications associated with coronary artery narrowing and plaque formation. These therapies include statins, beta blockers, ACE inhibitors, nitrates, calcium channel blockers, and other cardiovascular medications that help control cholesterol levels, regulate blood pressure, improve blood flow, and reduce the risk of myocardial infarction and other cardiovascular events. The growing emphasis on preventive cardiology and early intervention continues to strengthen demand for effective CAD therapeutics globally.

The market expansion is further supported by increasing investments in cardiovascular research, favorable reimbursement policies, growing awareness regarding heart health, and the introduction of innovative therapies such as PCSK9 inhibitors, RNA-based cholesterol-lowering drugs, and gene-editing approaches. Furthermore, the integration of digital health technologies, remote patient monitoring solutions, and AI-assisted cardiovascular care is creating favorable conditions for market growth.

Market Dynamics

The Coronary Artery Disease Therapeutics Market is influenced by a combination of epidemiological, technological, regulatory, and healthcare-access factors.

A major growth driver is the increasing prevalence of coronary artery disease and associated cardiovascular risk factors worldwide. Rising rates of obesity, diabetes, hypertension, smoking, and physical inactivity continue to contribute significantly to CAD incidence. As cardiovascular diseases remain the leading cause of mortality globally, healthcare systems are increasingly prioritizing preventive and long-term cardiovascular care, resulting in sustained demand for therapeutic interventions.

Another key growth driver is the increasing adoption of advanced lipid-lowering and cardioprotective therapies. The introduction of PCSK9 inhibitors, siRNA-based therapies such as inclisiran, and emerging gene-editing technologies targeting cholesterol metabolism pathways is improving treatment outcomes for high-risk patients. Growing clinical evidence supporting intensive cholesterol management and cardiovascular risk reduction is encouraging broader physician adoption of innovative therapies.

Technological advancements are also contributing significantly to market growth. The integration of artificial intelligence, telecardiology platforms, wearable cardiac monitoring devices, and digital patient-support programs is enhancing disease management, improving medication adherence, and facilitating early intervention. These innovations are helping healthcare providers deliver more personalized and efficient cardiovascular care.

However, the market faces challenges including the high cost of advanced cardiovascular therapies, limited accessibility in low- and middle-income countries, lengthy regulatory approval processes, and pricing pressures from healthcare payers. Despite these challenges, continued innovation in cardiovascular medicine, expanding healthcare infrastructure, and growing awareness of preventive care are expected to support long-term market expansion.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Coronary Artery Disease Therapeutics Market based on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Gilead, Novartis, Pfizer, Bayer, Merck & Co., GlaxoSmithKline plc, Mylan N.V.
• Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
• The Coronary Artery Disease Therapeutics Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
• Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Coronary Artery Disease Therapeutics Market

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2026-2033)
• Beta Blockers
• Statins
• ACE Inhibitors
• Nitrates
• Calcium Channel Blockers
• Others
• By Distribution Channel (Revenue, USD Bn, 2026-2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region (Revenue, USD Bn, 2026-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• AstraZeneca
• Gilead
• Novartis
• Pfizer
• Bayer
• Merck & Co.
• GlaxoSmithKline Plc
• Mylan N.V.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Disease Type Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Coronary Artery Disease Therapeutics Market, By Drug Type, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Beta Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Statins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• ACE Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Nitrates
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Calcium Channel Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Coronary Artery Disease Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Coronary Artery Disease Therapeutics Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Gilead
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Novartis
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Bayer
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

8. Section

• References
• Research Methodology
• About Us